Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in ongoing Phase 1 clincial trial SAN JOSE, Calif., April 7, 2026...